NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
5 hedge funds and large institutions have $147K invested in NLS Pharmaceutics Warrant in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
0.03% more ownership
Funds ownership: 5.47% → 5.5% (+0.03%)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
44% less capital invested
Capital invested by funds: $261K → $147K (-$114K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$1.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.09K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $75K | – | +1 | +0% |
|
|
ACM
2
Altium Capital Management
New York
| $30K | – | – | – |
|
|
AC
3
Ayrton Capital
Westport,
Connecticut
| $25.5K | – | – | – |
|
4
Hudson Bay Capital Management
Stamford,
Connecticut
| $15K | – | – | – |
|
|
CS
5
Clear Street
New York
| $1.29K | +$1.42K | +8,600 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$1.09K | -3,745 | Closed |
|
NLSPW Hedge Fund Activity: Q1 2023 in Review
5 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q1 2023, worth a combined $147K — down 44% from $261K a quarter earlier.
Fund positioning in NLSPW was balanced in Q1 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Clear Street, opening a new position worth an estimated $1.42K. The largest seller was UBS Group, exiting entirely with an estimated $1.09K sold.
- 5 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $147K of NLS Pharmaceutics Warrant stock for Q1 2023, down 44% quarter-over-quarter.
- 1 fund opened new NLS Pharmaceutics Warrant positions in Q1 2023 and 1 closed out, a net change of 0 holders.
- The largest NLS Pharmaceutics Warrant buyer in Q1 2023 was Clear Street, an estimated $1.42K added.
- The largest NLS Pharmaceutics Warrant seller in Q1 2023 was UBS Group, an estimated $1.09K sold.
Based on aggregated 13F filings for Q1 2023.